[{"data":1,"prerenderedAt":178},["ShallowReactive",2],{"drug-meropenem-vaborbactam":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":66,"warnings":76,"renal":84,"monitoring":94,"interactions":95,"review":96,"examples":99,"atc":105,"iran":107,"usApproval":114,"links":120,"populations":135},"meropenem-vaborbactam",1,{"fa":7,"en":8},"مروپنم-واباربکتام","Meropenem-vaborbactam","anti-infectives",{"fa":11,"en":12},"کارباپنم + مهارکننده بتالاکتاماز","Carbapenem + beta-lactamase inhibitor",[14],{"name":15,"market":16},"Vabomere","US",[18,19,20,21],"vabomere","vaborem","وابومر","مروپنم واباربکتام",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"vial-2","powder-for-injection","iv","2 g vial (meropenem 1 g + vaborbactam 1 g)",{"amount":29,"unit":30,"perUnit":31},2000,"mg","vial",[16],[34],{"source":35,"section":36},"fda-vabomere","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":52,"durationDays":55,"notes":57},"cuti","urinary-tract-infection",{"fa":42,"en":43},"عفونت ادراری عارضه‌دار و پیلونفریت (۱۸ سال به بالا) — ۴ g هر ۸ ساعت، انفوزیون ۳ ساعته، تا ۱۴ روز","Complicated UTI including pyelonephritis (≥18 years) — 4 g every 8 h as a 3-hour infusion, up to 14 days",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":50,"dosesPerDay":51},4000,3,[53],{"source":35,"section":54},"2.1",{"min":5,"max":56},14,[58],{"text":59,"refs":62},{"fa":60,"en":61},"دوز به‌صورت مجموع مروپنم + واباربکتام (۲ ویال). فقط با سالین ۰٫۹٪ سازگار است.","Dose as total meropenem + vaborbactam (2 vials). Compatible only with 0.9% sodium chloride.",[63,64],{"source":35,"section":54},{"source":35,"section":65},"2.4",[67],{"id":68,"severity":69,"text":70,"refs":73},"hyper","block",{"fa":71,"en":72},"حساسیت به مروپنم، واباربکتام یا هم‌گروه‌ها؛ آنافیلاکسی با بتالاکتام‌ها.","Hypersensitivity to meropenem, vaborbactam or same-class drugs; anaphylaxis with beta-lactams.",[74],{"source":35,"section":75},"4",[77],{"text":78,"refs":81},{"fa":79,"en":80},"حساسیت؛ تشنج؛ کاهش سطح والپروئیک‌اسید و تشنج ناگهانی؛ ترومبوسیتوپنی؛ اسهال C. difficile؛ رابدومیولیز.","Hypersensitivity; seizures; reduced valproic acid levels with breakthrough seizures; thrombocytopenia; C. difficile diarrhoea; rhabdomyolysis.",[82],{"source":35,"section":83},"5",[85],{"egfrBelow":86,"severity":87,"text":88,"refs":91},50,"warn",{"fa":89,"en":90},"eGFR زیر ۵۰: ۳۰ تا ۴۹ → ۲ g هر ۸ ساعت؛ ۱۵ تا ۲۹ → ۲ g هر ۱۲ ساعت؛ زیر ۱۵ → ۱ g هر ۱۲ ساعت؛ همودیالیز: پس از دیالیز.","eGFR \u003C50: 30–49 → 2 g every 8 h; 15–29 → 2 g every 12 h; \u003C15 → 1 g every 12 h; haemodialysis: after dialysis.",[92],{"source":35,"section":93},"2.2, Table 1",[],[],{"status":97,"reviewer":98,"date":98},"unverified",null,[100],{"regimen":39,"formulation":24,"input":101,"expect":104},{"ageYears":102,"weightKg":103},60,70,{"perDose":50,"dosesPerDay":51},[106],"J01DH52",{"status":108,"refs":109},"not-found",[110],{"source":111,"section":112,"url":113},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Meropenem-vaborbactam",{"kind":115,"refs":116,"id":119},"NDA",[117],{"source":35,"section":118},"SPL approval \u002F marketing category","NDA209776",[121,124,128,132],{"kind":122,"url":123,"label":119},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=209776",{"kind":125,"url":126,"label":127},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d","FDA Vabomere",{"kind":129,"url":130,"label":131},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa617048.html","Meropenem and Vaborbactam Injection",{"kind":133,"url":134,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01DH52",{"pregnancy":136,"lactation":145,"pediatric":153,"geriatric":162,"reproductive":170},{"level":137,"text":138,"quote":141,"refs":142},"caution",{"fa":139,"en":140},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Fetal malformations were observed in vaborbactam-treated rabbits, therefore advise pregnant women of the potential risks to the fetus.",[143],{"source":35,"section":144},"8.1",{"level":137,"text":146,"quote":149,"refs":150},{"fa":147,"en":148},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Meropenem has been reported to be excreted in human milk.",[151],{"source":35,"section":152},"8.2",{"level":154,"text":155,"quote":158,"refs":159},"not-established",{"fa":156,"en":157},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of VABOMERE in pediatric patients (younger than 18 years of age) has not been established.",[160],{"source":35,"section":161},"8.4",{"level":137,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.",[168],{"source":35,"section":169},"8.5",{"level":137,"text":171,"quote":174,"refs":175},{"fa":172,"en":173},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Use of VABOMERE may reduce the effectiveness of hormonal contraceptives.",[176],{"source":35,"section":177},"8.3",1792444410254]